Dr.DermMIA said:The manufacturing argument is the underrated one.
This answered a question I did not know how to ask. Sending this to two other people who asked me the same thing last week.
Adding the clinical framing, because it changes how the question reads. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.
Dr.EndoEP said:Read four things before the headline number.
Pushing back on Dr.EndoEP here. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsOne concrete data point for the thread. Give anything pharmacological four weeks before you judge it, and give anything measured weekly a four-point rolling average before you call it a trend.
Moderator note: leaving this open. It is being argued well and the disagreement is the useful part. Carry on.